Yuan Zhao, NP
Primary Care · El Segundo, CANPI 1679122592
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,485, more than ten times the $236 reported in 2022. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$894
- Abbott$726
- Lilly USA, LLC$507
- Ascensia Diabetes Care US Inc.$442
- Ascendis Pharma Endocrinology Inc$335
- Amgen$284
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,17998%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $894 |
| Abbott | 42 | $726 |
| Lilly USA, LLC | 32 | $507 |
| Ascensia Diabetes Care US Inc. | 34 | $442 |
| Ascendis Pharma Endocrinology Inc | 11 | $335 |
| Amgen | 7 | $284 |
| Averitas Pharma Inc. | 9 | $270 |
| Xeris Pharmaceuticals, Inc. | 11 | $234 |
| AbbVie | 6 | $209 |
| Novartis | 7 | $192 |
| Boehringer Ingelheim | 6 | $170 |
| Tandem Diabetes Care, Inc. | 6 | $159 |
| Corcept Therapeutics | 5 | $132 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $125 |
| Mannkind Corporation | 3 | $110 |
| Insulet Corporation | 2 | $77 |
| Organon | 2 | $75 |
| Medtronic | 3 | $70 |
| BETA Bionics, Inc. | 4 | $47 |
| IBSA Pharma Inc. | 2 | $42 |
| RGH Enterprises LLC | 1 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Antares Pharma, Inc. | 1 | $30 |
| Bayer | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Amphastar Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$235
- JYNARQUE$125
- FREESTYLE LIBRE 3$114
- Yorvipath$110
How this compares
$5,264 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 471 | $519,498 |
| MounjaroTirzepatide | 122 | $147,595 |
| JardianceEmpagliflozin | 70 | $79,286 |
| JanuviaSitagliptin Phosphate | 49 | $70,333 |
| TrulicityDulaglutide | 62 | $65,236 |
| ProliaDenosumab | 31 | $51,456 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $42,074 |
| FarxigaDapagliflozin Propanediol | 30 | $32,750 |
| TradjentaLinagliptin | 21 | $28,015 |
| Humalog Kwikpen U-100Insulin Lispro | 119 | $27,973 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 202 | $22,783 |
| Humalog Kwikpen U-200Insulin Lispro | 24 | $22,204 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $21,099 |
| RybelsusSemaglutide | 11 | $20,475 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $17,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $894 | $539,973482 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $507 | $216,419198 claims |
| Boehringer IngelheimJardiance, Tradjenta | $170 | $107,30191 claims |
| AmgenProlia | $284 | $51,45631 claims |
| AbbVieSynthroid | $209 | $5,71163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in El Segundo
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
- Lynda TranHuntington Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.